Quarterly ResultMay 15, 2026, 04:39 PM
Outlook Therapeutics Reports Q2 Net Loss $4.45M; Going Concern Doubt
AI Summary
Outlook Therapeutics reported a net loss of $4.45 million for the three months ended March 31, 2026, and $27.51 million for the six months. The company disclosed a working capital deficit and an accumulated deficit of $633.22 million, leading management to express substantial doubt about its ability to continue as a going concern. Outlook Therapeutics is actively seeking additional financing to fund future operations and commercialization efforts. The company also provided updates on its Biologics License Application for ONS-5010/LYTENAVA, having received a third Complete Response Letter from the FDA, while commercial sales of LYTENAVA commenced in Germany and the UK in June 2025.
Key Highlights
- Net loss for Q2 2026 was $4.45 million, compared to $46.36 million in Q2 2025.
- Six-month net loss was $27.51 million, compared to $28.98 million in prior year.
- Accumulated deficit reached $633.22 million as of March 31, 2026.
- Cash and cash equivalents stood at $7.75 million as of March 31, 2026.
- Company expressed substantial doubt about its ability to continue as a going concern.
- Received third FDA Complete Response Letter for ONS-5010/LYTENAVA BLA.
- Commercial sales of LYTENAVA commenced in Germany and UK in June 2025.
- Net cash used in operating activities was $22.77 million for six months.
Price Impact
More from OTLK